# Immunicon

**Canonical:** https://apis.io/providers/immunicon/  
**APIs profiled:** 0

Immunicon Corporation (NASDAQ IMMC) was a Huntingdon Valley, Pennsylvania biotechnology company that pioneered immunomagnetic cell-selection technology for isolating and characterizing rare circulating tumor cells (CTCs) from blood. It developed the CellSearch and CellTracks diagnostic platforms, licensed to Veridex, LLC (a Johnson & Johnson company) for oncology use. Immunicon filed for Chapter 11 bankruptcy in 2008 and was acquired by Veridex/Johnson & Johnson; the CellSearch platform later passed to Menarini Silicon Biosystems. The company was backed by Canaan Partners and publishes no public API or developer surface.

## Kin Score — 2.2 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 2.2).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 0.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Biotechnology, Diagnostics, Oncology, Medical Devices, Life Sciences, Defunct

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/immunicon/). Scores are computed from the provider's own public artifacts under a published rubric.